Aurora Cannabis Announces Financial Results for the Third Quarter of Fiscal Year 2019

[ad_1]

<p class = "canvas-atom text-canvas Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Solid revenue growth across all channels at $ 65.1 million
Production volumes double as production costs per unit decrease
On track to generate positive EBITDA as of the fourth quarter of fiscal year 2019 "data-reactid =" 11 ">Solid revenue growth across all channels at $ 65.1 million
Production volumes double as production costs per unit decrease
On track to generate positive EBITDA as of the fourth quarter of fiscal year 2019

TSX: ACB | NYSE: ACB

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "EDMONTON, May 14, 2019 / CNW / – & nbsp Aurora Cannabis Inc. (the "Business" or "Dawn") (CBA) (CBA), announced today its financial and operating results for the third quarter ended March 31 ^st, 2019. "data-reactid =" 13 "> EDMONTON, May 14, 2019 / CNW / – Aurora Cannabis Inc. (the"Business" or "Dawn") (ACB) (ACB), today announced its financial and operating results for the third quarter ended March 31 ^st, 2019.

Highlights of the third quarter of 2019

<p class = "canvas-atom text-canvas Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "(Unless otherwise noted, comparisons are made between the results for the third quarter of 2019 and those of the second quarter of 2019)"data-reactid =" 15 ">(Unless otherwise noted, comparisons are made between the results for the third quarter of 2019 and those of the second quarter of 2019)

Strong and consistent revenue growth of 20% on average across all key markets, driven by the successful ramp-up of the company's production and the continued strong performance of the Canadian consumer and the Canadian and international markets for Cannabis for Purposes medical:
Growth in the Company's medical patient base, up 5% to 77,136. As of the date of this release, Aurora has 82,745 active enrolled patients, an additional 7% increase, and continues to register new patients as product availability increases.
Cash costs related to production per gram decreased by 26% to establish at USD 1.42 per gram, the initial impact of the magnitude and effectiveness of Aurora Sky having begun to materialize.
Production volume increased 99% to 15,590 kg, up 1,200% year-on-year. The increase in production accelerated during the quarter, with most of the volume harvested in the second half of the quarter.
Selling, administrative and other overhead expenses stabilized with a modest increase of 1%, reflecting Aurora's ongoing commitment to rigorous cost management.
Average selling price per gram decreased slightly due to product mix effects (larger contribution from wholesale consumers), extraction capacity constraints resulting in extract-based products accounting for 18 % of net sales of cannabis and the first impact of the excise tax on medical cannabis for the first full quarter.
Adjusted EBITDA loss increased 20% to $ 36.6 million, as the Company continues to achieve positive EBITDA results starting in the fourth quarter of 2019 as operations continue to progress.
In January 2019, Aurora completed a US $ 345 million convertible note offering, the proceeds being used to continue the company's growth in Canada and internationally. The IFRS accounting standards require a mark-to-market adjustment at the end of each period for the derivative portion of these notes. Due to the rise in Aurora's share price since the issuance of the notes, the Company recorded a non-cash fair value loss of $ 102 million in the third-quarter income statement. quarter of 2019.

Management Commentary

"I am exceptionally proud of our company and team as Aurora continues to implement its national and international growth strategy, and we have achieved solid revenue growth and strong operating results over the past year. a challenging quarter for the entire industry – long-term sustainability, "said Terry Booth, CEO. "During the quarter, we officially welcomed Nelson Peltz, a key strategic advisor, who was incredibly engaged, collaborative and strategically focused to help us continue to grow in global markets and with mature businesses in adjacent industries."

Glen Ibbott, CFO, added, "Aurora is an extremely active and diversified company, a leader in cannabis research, product development, culture, global scale and revenue growth. the fronts, it's time to change course The company we have built with determination, both organic growth and targeted acquisitions, has provided a unique opportunity: continue to lead the sector in terms of revenue growth while clearing a positive operating profit in the short term. "

Key financial and operating metrics for the third quarter of 2019

(in thousands of dollars, unless otherwise indicated)	Q3 2019	Q2 2019	% Change	Q3 2018	% Change
Financial results
Gross revenue	$ 75,238	$ 62,000	21%	$ 16,100	367%
Net revenue ⁽¹⁾	$ 65,145	$ 54,178	20%	$ 16,100	305%
Cannabis net income ⁽¹⁾	$ 58,652	$ 47,577	23%	$ 10,810	443%
Net income from medical cannabis	$ 29,075	$ 25,994	12%	$ 10,810	169%
Net consumption of cannabis	$ 29,577	$ 21,583	37%	N / A	N / A
Gross Margin on Cannabis Net Income ⁽¹⁾	55%	54%	1%	59%	(4)%
Selling, general and administrative expenses	$ 67,104	$ 66,362	1%	$ 15,727	(327)%
Adjusted EBITDA ⁽²⁾	($ 36,617)	($ 45,524)	(20)%	($ 12,904)	184%
(Loss) earnings attributable to common shareholders	($ 158,354)	($ 237,752)	(33)%	($ 19,215)	724%

Balance sheet
Working capital	$ 469,729	$ 274,629	71%	$ 338,476	39%
Cannabis stock and biological assets ⁽²⁾	$ 118,023	$ 79,924	48%	$ 28,478	314%
Total assets	$ 5,549,780	$ 4,875,884	14%	$ 1,671,400	232%

Operational Results – Cannabis
Cost disbursed to produce per gram of dried product sold ⁽²⁾	$ 1.42	$ 1.92	(26)%	$ 1.53	(7)%
Active Registered Patients	77 136	73,579	5%	45,776	69%
Average net selling price per gram ⁽²⁾	$ 6.40	$ 6.80	(6)%	$ 7.99	(20)%
Kilograms produced	15,590	7,822	99%	1,206	1.193%
Kilograms sold	9,160	6,999	31%	1,353	577%


⁽¹⁾	Net Revenues represent our total gross revenues, excluding excise taxes collected by the Canada Revenue Agency ("CRA") on the sale of cannabis products for medical and recreational purposes as of October 17, 2018.
⁽²⁾	These non-GAAP terms and measures are defined or reconciled in Aurora's 2011 third quarter MD & A.

Perspective

Aurora Sky and Bradford facilities are now operating at full capacity. As a result, the company's annualized production rate at its operational facilities exceeds 150,000 kg per year, based on planted rooms.

Aurora is reiterating its fourth quarter target with available-for-sale production of more than 25,000 kg. Management intends to allocate some of this capacity to its inventory for the manufacture of new products. Aurora remains focused on the need for vassals and some edible products for launch under the new Canadian consumer market regulations, scheduled for the end of the calendar year.

With the acceleration of production, the company continues to increase its manufacturing capacity through innovation and technologies to reduce the time between harvesting and marketing. The company expects increased processing, packaging and delivery efficiency in the fourth quarter and beyond will accelerate product availability.

The supply in Europe and other international markets is expected to increase, more and more Aurora production facilities receiving European GMP certification. Bradford's facilities have recently been audited for European GMP certification. In the third quarter, the company began exporting full spectrum cannabis extracts to Germany. Management expects these sales to contribute to growth given the higher margins of the statements.

The oil extraction capacity was a constraint in the second and third quarters of 2019. After the end of the quarter, Aurora increased its internal extraction capacity to nearly 7,000 kg per quarter and will reach nearly 16,000 kg per quarter during the first quarter. In addition, the company's mining partner, Radient Technologies, is ramping up commercial production at its Edmonton facility. As a result, Aurora expects an increase in the production of extract-based products and its impact will begin to materialize towards the end of the fourth quarter. This increase in internal and external extraction capacity will strengthen Aurora's ability to produce derivatives on a large scale, which management believes will have a positive impact on revenues and gross margin.

With Aurora Sky now operating at full capacity, the company anticipates a continued reduction in production and manufacturing costs, which will allow cash costs per gram to continue to decline. Management reiterates its expectation that the average cash cost of production per gram at its Sky category facilities will be less than $ 1.

With disciplined cost management, the company expects modest growth in selling, administrative and other overhead expenses for the remainder of the year. As a result, management anticipates that with continued revenue growth and lower cash costs per gram, Aurora is well positioned to achieve positive EBITDA starting in the fourth quarter of 2019 (Q2 2019 calendar).

Q3 2019 Update of facilities and production

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Aurora defines the production rate as the capacity of all plant chambers approved by the regulator for sale, using mature annualized harvests based on historical yield per plant. These targeted returns have been met or exceeded in all of Aurora's current operating facilities. To view a video preview of Aurora's production facilities, click here: https://youtu.be/irTfAXbFS38. "data-reactid =" 48 "> Aurora defines the production rate as the capacity of all plant chambers approved by the regulator for sale, using mature annualized harvests based on historical yield per plant. These targeted returns have been met or exceeded in all of Aurora's current operating facilities. To view a video preview of Aurora's production facilities, click here: https://youtu.be/irTfAXbFS38.

Construction at Aurora Sky is complete and all growth rooms have been licensed by Health Canada. Fully planted, Aurora Sky operates at its maximum rated capacity of over 100,000 kg per year.
Health Canada has licensed all Bradford chambers, which have been fully developed. The plant did not receive any major observations during its audit to obtain EU GMP certification. Obtaining this certificate will greatly increase the ability of the company to ship its products to the European market.
The first salable harvest at Aurora Nordic 1 is scheduled for the end of the fourth quarter of 2019, with sales of the product expected to be in December 2019 or as soon as regulatory approvals are provided. First harvests for testing and licensing were completed.
The construction of Aurora Sun is progressing well and the facility is expected to be ready to be planted by mid-July 2020. Aurora Sun will measure 1.62 million square feet, representing an increase of 33%. % compared to its originally planned size.

Installation of a glass roof structure at Aurora Sun, Medicine Hat, Alberta. (CNW Group / Aurora Cannabis Inc.)

Whistler Alpha Lake is currently operating at its planned capacity of 480 kg / yr certified organic cannabis, using four culture rooms.
The construction of Whistler Pemberton is about to be completed in the fourth quarter of 2019
During the last growing season in Europe, Agropro harvested 3,950 acres of hemp in Lithuania, Latvia and Estonia. For the next growing season, starting in May 2019, Agropro plans to sell 8,150 acres of hemp for harvest, which is expected to begin in August.

Q3 2019 and business highlights thereafter

Acquisitions

Acquisition of Whistler Medical Marijuana Corporation ("Whistler")
On March 1, 2019, Aurora acquired Whistler, an iconic Canadian organic cannabis brand, which offers a significant premium for its products in the Canadian medical and consumer markets. The company is currently expanding Whistler's operations and expects an increase in products available for sale for the remainder of the calendar year.
Acquisition of Hempco Food and Fiber Inc. ("Hempco")
On April 16, 2019, the Company signed a letter of intent with Hempco to acquire all of the issued and outstanding shares of Hempco. The acquisition will strengthen the infrastructure of industrial hemp and CBD from the company's hemp.
Acquisition of Chemi Pharmaceuticals Inc. ("Chemi")
On April 24, 2019, the Company acquired Chemi, an Ontario-based laboratory specializing in high quality analytical services for the pharmaceutical and cannabis industries. The acquisition aims to expand the company's analytical services for derivatives.

Strategic developments

Appointment of Nelson Peltz
On March 13, 2019, the company appointed Nelson Peltz as Strategic Advisor, who will work with Aurora to explore opportunities for expansion and partnership globally. Management believes that the Company is well positioned to build partnerships in several industry sectors and is working with Mr. Peltz and his team to evaluate opportunities.
Aurora Polaris
On February 12, 2019, the Company announced the construction of Aurora Polaris, a 300,000 square foot international logistics center and facility for the production of cannabis-based products on an industrial scale. Construction is proceeding as planned and the company expects work to be completed by the end of the calendar year. In anticipation of the new regulations, the company is installing temporary production lines in authorized spaces of its production infrastructure in Canada to ensure the availability for sale of a full range of products in Canada. substantial quantities, if any.

International Expansion

German tender for the production of cannabis
On April 5, 2019, the German Federal Institute of Drugs and Medical Devices selected the company among the three winners of a call for tenders for the cultivation and distribution of cannabis for medical purposes in Germany. Aurora got the highest score on 11 of the 13 lots selected and was given the maximum number assigned to a five LP. Aurora has started the construction work of a facility in Germany and its product is expected to arrive on the German market in October 2020. Management expects that becoming a local producer will boost the notoriety of the brand and market development in a large and important market.
Exports of medical cannabis in the United Kingdom
On February 11, 2019, the Company completed its first commercial export of cannabis oil to the United Kingdom. In the new UK framework, medical specialists can legally prescribe cannabis-based medicines when they agree that their patients could benefit from this treatment.
Expansion in Portugal
On February 26, 2019, the company created Aurora Portugal Lda. by an agreement to acquire a 51% stake in Gaia Pharm Lda. The construction of a cannabis production center compliant with European GMP standards is underway in Portugal.
Exports of cannabis oil in Germany
On March 11, 2019, the Company began selling cannabis oils in German pharmacies. The Aurora full-spectrum extract is differentiated in a market primarily served by synthetic cannabinoids. In this regard, management believes that the Company has a significant competitive advantage in building leadership, brand awareness and pioneer sales growth in this high margin segment.

Financing activities

Offer of convertible notes
On January 24, 2019, the Company closed an offering of convertible notes for gross proceeds of US $ 345 million to support Canadian and international expansion initiatives, future acquisitions and general corporate requirements. business, including working capital requirements to continue the accelerated growth of the company.
Filing of Base Shelf Prospectus and Prospectus Supplement for Market Placement
On May 10, 2019, the Company filed a final short form base shelf prospectus (the "Shelf Prospectus") with the securities commissions of each of the provinces of Canada, with the exception of Quebec, and a declaration of 39, prior registration with United States Securities. and Exchange Commission on Form F-10. These documents allow the Company to classify the distribution, under a prospectus in Canada and in the United States, of common shares, warrants, warrants, debt securities or any combination thereof (all of which of such securities, "Shelf Securities") during the 25-month period during which the final short form base shelf prospectus remains in effect. The specific terms of any future offering under the shelf prospectus will be set forth in a prospectus supplement. Any prospectus supplement will be filed with the applicable securities regulatory authorities in connection with such offering.

On May 14, 2019, the Company filed a prospectus supplement (the "Prospectus Supplement") in the Shelf Prospectus. In connection with the Prospectus Supplement, Aurora entered into a contract of sale dated May 14, 2019 with Cowen and Company, LLC ("Cowen") and BMO Capital Markets ("BMO"), which will act as Agents. sellers (the "selling agents") for the sale of Aurora common shares (the "Common Shares") through "to the market" distributions "on the New York Stock Exchange in the United States. Under the terms of the sales contract and applicable regulatory requirements, common shares of a maximum aggregate amount of USD 400,000,000 may be issued and sold on an occasional basis at Aurora's discretion over a maximum period of time. The common shares will be distributed at the prevailing market prices at the time of the sale of such common shares and, as a result, prices may vary between the purchasers and during the distribution period. , where appropriate, will be used for General Conditions of Business, including: (i) working capital; (ii) potential future acquisitions; (iii) repayment of the debt; and (iv) capital expenditures. The volume and timing of sales, if any, of common shares are at the discretion of Aurora.

Aurora plans to use the net proceeds of the prospectus to support its expansion initiatives, global partnership strategy and to continue the accelerated growth of the Company.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The shelf prospectus and supplement have been filed on SEDAR and the US version of the shelf prospectus and prospectus supplement have been posted on the SEC's website (www.sec.gov). "data-reactid =" 106 "> The prospectus and prospectus supplement have been filed on SEDAR and the US version of the Prospectus and the Prospectus Supplement have been posted on the SEC's website (www.sec.gov).

<p class = "canvas-atom text-canvas Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "This press release does not constitute an offer to sell or the solicitation of an offer to purchase. No sale of such securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the Act. securities laws of such a jurisdiction."data-reactid =" 107 ">This press release does not constitute an offer to sell or the solicitation of an offer to purchase. No sale of such securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the Act. securities laws of such a jurisdiction.

Financial Supplement T3 2019

(in thousands of dollars)	Three months ended
(in thousands of dollars)	March, 31st, 2019	The 31st of December, 2018
Net income from medical cannabis
Cannabis dried in Canada	16,576	15,411
Cannabis dried from the EU	4,004	2,853
Cannabis extracts ⁽¹⁾	8,495	7.731
Total Net Receipts of Medical Cannabis	29.075	25,994

Net consumption of cannabis
Dried cannabis	27,461	18,796
Cannabis extracts ⁽¹⁾	2 116	2,787
Total net cannabis income	29,577	21,583

Total net cannabis income	58,652	47,577

(in thousands of dollars)	Three months ended		Nine months ended
(in thousands of dollars)	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
Net revenue	65,145	16,100	148,997	36,049
Design, engineering and construction services	(914)	(2,979)	(2,403)	(2,979)
Patient counseling services	(809)	(609)	(3,608)	(2,416)
Analytical testing services	(1,238)	–	(2.659)	–
Turnover of accessories and other cannabis products	(962)	(81)	(2,131)	(107)
Integrated business figure horizontally	(2,570)	(1.621)	(7,370)	(2.674)

Cannabis net income	58,652	10 810	130,826	27,873

Grant Options

The Company has granted a total of 383,000 options to purchase Aurora common shares to the directors and officers of the Company. The options vest annually over a 36-month period and have a weighted average exercise price of $ 9.35 per common share.

Conference call

Aurora will hold a teleconference tomorrow, May 15, 2019, to discuss these results. Terry Booth, Managing Director, Glen Ibbott, Chief Financial Officer, Cam Battley, Managing Director, and Michael Singer, Executive Chairman of the Board, will host the teleconference beginning at 10:30 am ET. A question and answer session will follow the presentation of the management.

Date:	Wednesday, May 15^th, 2019
Time:	10:30 am Eastern Time \| 8:30 am mountain time
Webcast:	https://bit.ly/2GRpDP3
Replay:	(416) 849-0833 or (855) 859-2056
	until midnight Eastern time on Wednesday, May 22, 2019
Reference number:	1103129


⁽¹⁾	Non-IFRS measures are defined in the Company's MD & A.

About Aurora

Headquartered in Edmonton, Alberta, Canada, with over 625,000 kg of financing capacity and sales and operations in 24 countries on five continents, Aurora is one of the largest and most important cannabis companies in the world. Aurora is vertically integrated and horizontally diversified across all key segments of the value chain, from engineering and facility design to research on cannabis selection and genetics, cannabis production and hemp, derivatives, development of high added value products, home grown, wholesale and retail.

Highly differentiated from its peers, Aurora has implemented a particularly advanced, consistent and efficient production strategy, based on facilities specifically designed to integrate state-of-the-art technologies into all processes, defined by extensive automation and customization, enabling large-scale production of low-cost quality. Designed to be replicated and scalable globally, our production facilities are designed to produce cannabis on a significant scale, with high quality, industry leading yields, and low production costs per gram. Each Aurora facility is built to meet European GMP standards. The EU GMP certification has been awarded to Aurora's first production facility in Mountain View County, to the MedReleaf Markham facility, and to its European medical cannabis distributor, Aurora Deutschland.

<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "In addition to the rapid organic growth of society and its strong execution on strategic M & A, which to date includes 16 wholly-owned subsidiaries – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, Biopharma H2, Urban Grower, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler and Chemi Pharmaceutical – Aurora stands out by its reputation as a partner and employer of choice in the global cannabis industry, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (RTI.V), Hempco Food and Fiber Inc. (HEMP.V), Cann Group Ltd. (CAN.AX), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (CTTH), Alcanna Inc. (CLIQ.TOHigh Tide Inc. (CSE: HITI) and EnWave Corporate (ENW.V). "data-reactid =" 127 "> In addition to the company's rapid internal growth and strong execution in strategic mergers and acquisitions, which to date includes 16 wholly-owned subsidiaries – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, Northern Lights of British Columbia, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler and Chemi Pharmaceutical – Aurora stands out by its reputation as a partner and partner in the world. An employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (RTI.V), Hempco Food and Fiber Inc. (HEMP.V), Cann Group Ltd. (CAN.AX), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private) , Wagner Dimas (private), CTT Pharmaceutic als (CTTH), Alcanna Inc. (CLIQ.TO), High Tide Inc. (CSE: HITI) and EnWave C orporate (ENW.V).

The Aurora common shares trade on the TSX and the NYSE under the symbol "ACB" and are part of the S & P / TSX Composite Index.

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "For more information about Aurora, please visit our investor website, investisseur.auroramj.com& nbsp; "data-reactid =" 129 "> For more information on Aurora, visit our investor website, investor.auroramj.com

Terry Booth, CEO
Aurora Cannabis Inc.

Déclarations prospectives et mesures sectorielles non conformes aux IFRS

Ce communiqué de presse fait référence à certaines mesures non conformes aux IFRS, y compris certains paramètres de l’industrie. Ces mesures et mesures ne sont pas reconnues. Les mesures en vertu des IFRS n’ont pas la signification qui leur est prescrite et, par conséquent, il est peu probable qu’elles soient comparables à des mesures similaires présentées par d’autres sociétés. Ces mesures sont fournies à titre d’information complémentaire à ces mesures IFRS en permettant de mieux comprendre nos résultats d’exploitation du point de vue de la direction. En tant que telles, ces mesures ne doivent pas être considérées isolément ni au lieu d’examiner nos informations financières présentées en vertu des IFRS. Le présent communiqué de presse utilise des mesures non définies par les IFRS, notamment les «BAIIA», le «taux de production», la «production disponible à la vente» et les «frais de vente, dépenses administratives et autres frais généraux». La production disponible à la vente et le taux de production sont des mesures d'exploitation couramment utilisées dans l'industrie mais peuvent être calculés différemment par rapport à d'autres sociétés de l'industrie. Ces mesures non conformes aux IFRS, y compris les mesures sectorielles, sont utilisées pour fournir aux investisseurs des mesures supplémentaires de notre performance opérationnelle qui pourraient ne pas être apparentes si elles ne reposaient que sur des mesures IFRS. Les définitions des mesures non conformes aux IFRS figurent dans nos états financiers, notre rapport de gestion et le présent communiqué de presse.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Ce communiqué de presse contient également des déclarations contenant certains des informations prospectives "au sens du droit des valeurs mobilières applicable (" déclarations prospectives "). Les déclarations prospectives sont souvent caractérisées par des mots tels que" plan "," poursuite "," attente "," projet "," intention " , "croire", "anticiper", "estimer", "peut", "sera", "potentiel", "proposé" et autres mots similaires, ou déclarations selon lesquelles certains événements ou conditions "peuvent" ou "vont" se produire et inclure , mais ne se limitent pas à la signature d’ententes définitives et à la conclusion de la transaction. Ces déclarations ne sont que des prédictions. Diverses hypothèses ont été utilisées pour tirer les conclusions ou établir les projections contenues dans les déclarations prospectives figurant dans le présent communiqué de presse. Les déclarations prospectives sont basées sur les opinions et estimations de la direction à la date à laquelle elles sont faites et sont sujettes à une variété de risques et d’incertitudes et d’autres facteurs susceptibles d’entraîner un écart considérable entre les événements ou les résultats réels et ceux projetés dans les déclarations prospectives. Ces risques incluent, sans toutefois s'y limiter, la capacité de retenir le personnel clé, la capacité de continuer à investir dans l'infrastructure pour soutenir la croissance, la capacité d'obtenir un financement à des conditions acceptables, la qualité continue de nos produits, l'expérience et la fidélisation de la clientèle, développement de l'utilisation par des tiers, gouvernementaux et non gouvernementaux, des adultes & nbsp; canaux de vente, estimation par la direction de la demande des consommateurs au Canada et dans les pays où la société exporte, attentes sur les résultats et les charges futurs, disponibilité de capitaux supplémentaires pour mener à bien les projets de construction et les améliorations des installations, risque de bonne intégration des activités et opérations acquises, capacité d'élargir et de maintenir les capacités de distribution, l'impact de la concurrence et la possibilité de modifications des lois, règles et réglementations de l'industrie. La Société n’a aucune obligation et décline expressément toute intention ou obligation de mettre à jour ou de réviser tout énoncé prospectif, que ce soit à la suite de nouvelles informations, d’événements futurs ou autrement, sauf si expressément requis par la loi applicable.& nbsp;"data-reactid =" 133 "> Ce communiqué inclut également des déclarations contenant certaines" informations prospectives "au sens du droit des valeurs mobilières applicable (" déclarations prospectives "). Les déclarations prospectives sont souvent caractérisées par des termes tels que "planifier", "continuer", "s'attendre à", "projeter", "avoir l'intention", "croire", "anticiper", "estimer", "peut", "sera", "potentiel", "proposé" et autres similaires des mots ou des déclarations indiquant que certains événements ou conditions "peuvent" ou "vont" se produire et inclure, mais ne se limitent pas à l'exécution d'accords définitifs et à la clôture de la transaction. Ces déclarations ne sont que des prédictions. Diverses hypothèses ont été utilisées pour Les conclusions prospectives sont basées sur les opinions et estimations de la direction à la date à laquelle elles sont formulées et sont soumises à divers risques et incertitudes, ainsi que d’autres facteurs qui pourraient ca utilisez des événements ou des résultats réels pour différer sensiblement de ceux projetés dans les déclarations prospectives. Ces risques incluent, sans toutefois s'y limiter, la capacité de retenir le personnel clé, la capacité de continuer à investir dans l'infrastructure pour soutenir la croissance, la capacité d'obtenir un financement à des conditions acceptables, la qualité continue de nos produits, l'expérience et la fidélisation de la clientèle, development of third party government and non-government adult-use sales channels, managements estimation of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, the ability to expand and maintain distribution capabilities, the impact of competition, and the possibility for changes in laws, rules, and regulations in the industry. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Aurora Cannabis Inc. (CNW Group/Aurora Cannabis Inc.)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-announces-financial-results-for-the-third-quarter-of-fiscal-2019-300850332.html" data-reactid="165">View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-announces-financial-results-for-the-third-quarter-of-fiscal-2019-300850332.html

SOURCE Aurora Cannabis Inc.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/14/c5618.html" data-reactid="184">View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/14/c5618.html

[ad_2]

Source link